EGFR is commonly overexpressed or mutated in many cancers, including non-small-cell lung cancer, colorectal cancer, glioblastoma, and breast cancer, where it promotes oncogenic signaling pathways that facilitate cancer cell proliferation. This evidence concerns the gene EGFR and colorectal cancer.